



## King's Research Portal

DOI:

[10.1016/j.jinf.2018.10.007](https://doi.org/10.1016/j.jinf.2018.10.007)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Marbach, H., Vizcay-Barrena, G., Memarzadeh, K., Otter, J. A., Pathak, S., Allaker, R. P., Harvey, R. D., & Edgeworth, J. D. (2018). Tolerance of MRSA ST239-TW to chlorhexidine-based decolonization; evidence for keratinocyte invasion as a mechanism of biocide evasion. *Journal of Infection*.  
<https://doi.org/10.1016/j.jinf.2018.10.007>

### Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### Take down policy

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

## Accepted Manuscript

Tolerance of MRSA ST239-TW to chlorhexidine-based decolonization; evidence for keratinocyte invasion as a mechanism of biocide evasion

Helene Marbach , Gema Vizcay-Barrena , Kaveh Memarzadeh ,  
Jonathan A. Otter , Smriti Pathak , Robert P. Allaker ,  
Richard D. Harvey , Jonathan D. Edgeworth

PII: S0163-4453(18)30312-8  
DOI: <https://doi.org/10.1016/j.jinf.2018.10.007>  
Reference: YJINF 4181



To appear in: *Journal of Infection*

Received date: 15 July 2018  
Revised date: 30 September 2018  
Accepted date: 20 October 2018

Please cite this article as: Helene Marbach , Gema Vizcay-Barrena , Kaveh Memarzadeh , Jonathan A. Otter , Smriti Pathak , Robert P. Allaker , Richard D. Harvey , Jonathan D. Edgeworth , Tolerance of MRSA ST239-TW to chlorhexidine-based decolonization; evidence for keratinocyte invasion as a mechanism of biocide evasion, *Journal of Infection* (2018), doi: <https://doi.org/10.1016/j.jinf.2018.10.007>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Highlights**

- MRSA clones with a low chlorhexidine MIC phenotype can still survive decolonization regimes
- *in vivo* decolonization tolerance of ST239-TW may not be due to the presence of *qacA* alone
- elevated fibrinogen and fibronectin binding by ST239-TW is indicative of increased cell uptake
- ST239-TW shows increased chlorhexidine survival when adhered and internalized to keratinocytes

**Title: Tolerance of MRSA ST239-TW to chlorhexidine-based decolonization;  
evidence for keratinocyte invasion as a mechanism of biocide evasion**

Helene Marbach<sup>a1</sup>, Gema Vizcay-Barrena<sup>b</sup>, Kaveh Memarzadeh<sup>c</sup>, Jonathan A. Otter<sup>d2</sup>, Smriti Pathak<sup>d</sup>, Robert P. Allaker<sup>c</sup>, Richard D. Harvey<sup>a3\*</sup> and Jonathan D. Edgeworth<sup>d</sup>

\*Corresponding author: Richard D. Harvey, Institute of Pharmacy, Pharmaceutical Technology and Biopharmaceutics Biopharmacy group, Martin-Luther-Universität, Halle-Wittenberg, Germany, Ground floor - Room 15, Wolfgang-Langenbeck-Str. 4, 06120 Halle (Saale) Germany. Phone: +49 (0) 345 55-25215, email: richard.harvey@pharmazie.uni-halle.de

- a. Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College London, UK.
- b. Centre for Ultrastructural Imaging, King's College London, Guy's Campus, London, UK.
- c. Queen Mary, University of London, Barts and The London School of Medicine and Dentistry, London, UK.
- d. Centre for Clinical Infection and Diagnostics Research (CIDR), Department of Infectious Diseases, King's College London & Guy's and St. Thomas' NHS Foundation Trust (GSTT), London, UK.

Current affiliations:

<sup>1</sup>Functional Microbiology, Institute of Microbiology, Department of Pathobiology, University of Veterinary Medicine Vienna, Austria.

<sup>2</sup>National Institute for Healthcare Research Health Protection Research Unit (NIHR HPRU) in HCAIs and AMR at Imperial College London and Public Health England.

<sup>3</sup>Institute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale) Germany.

## ABSTRACT

Information on genetic determinants of chlorhexidine tolerance (*qacA* carriage and MIC) in vitro is available, although evidence of the clinical impact and mechanisms remain poorly understood. We investigated why, following chlorhexidine intervention, prevalent epidemic MRSA ST22 and ST36 clones declined at an ICU, whilst an ST239-TW clone did not. The chlorhexidine tolerant ST239-TW phenotypes were assessed for their protein binding, cell adhesion and intracellular uptake potential.

### *Methods*

Six ST22, ST36 and ST239-TW bloodstream infection isolates with comparable chlorhexidine MICs were selected from a 2-year outbreak in an ICU at Guy's and St. Thomas' Hospital. Isolates were tested for fibrinogen and fibronectin binding, and adhesion/internalization into human keratinocytes with and without biocide.

### *Results*

Binding to fibrinogen and fibronectin, adhesion and intracellular uptake within keratinocytes ( $P < 0.001$ ) and intracellular survival in keratinocytes under chlorhexidine pressure (ST22 3.18%, ST36 4.57% vs ST239-TW 12.79%;  $P < 0.0001$ ) was consistently higher for ST239-TW.

### *Conclusions*

We present evidence that MRSA clones with similarly low in vitro tolerance to chlorhexidine exhibit different in vivo susceptibilities. The phenomenon of *S. aureus* adhesion and intracellular uptake into keratinocytes could therefore be regarded as an additional mechanism of chlorhexidine tolerance, enabling MRSA to evade infection control measures.

Key words: ST239-TW, chlorhexidine tolerance, decolonization, adhesion, intracellular uptake, biocide evasion

## INTRODUCTION

Over the past 20 years there have been two dominant pandemic healthcare-associated methicillin-resistant *Staphylococcus aureus* (HA-MRSA) clones in the UK, EMRSA-15 (ST22) and EMRSA-16 (ST36), with lower prevalence of other clones (ST8, ST239, ST5 and ST247). HA-MRSA rates have decreased significantly since the mid-2000's<sup>1-4</sup> following the introduction of a comprehensive UK-wide infection control program comprising re-enforcement of basic infection control practices and targeted measures of screening, contact precautions, patient isolation and decolonization.<sup>4-7</sup> We previously reported an approximate 70% reduction in transmission of endemic MRSA clones following introduction of chlorhexidine-based universal decolonization into the intensive care unit (ICU) at Guy's and Thomas' Hospital (GSTT), London in 2004.<sup>4</sup> This is consistent with a number of studies reporting reductions in MRSA transmission, bacteremia and colonization following introduction of universal chlorhexidine skin washes.<sup>8-10</sup>

Introduction of heightened infection control measures also uncovered a hidden two-year outbreak due to an ST239 clone (ST239-TW) which probably originated from Singapore and is one of five major ST239 clades (the Thai clade).<sup>11</sup> While transmission of ST22 and ST36 clones decreased following the introduction of decolonization with chlorhexidine on the GSTT ICU, the transmission of ST239-TW did not.<sup>4,8,12-14</sup>

We previously reported that ST239-TW had an increase in chlorhexidine MBC compared with non-TW MRSA isolates (ST22 and ST36), based on analysis of five skin isolates identified during the outbreak.<sup>8</sup> MRSA blood stream infection (BSI) isolates from the same outbreak were analyzed for their CHG (chlorhexidine digluconate) MIC in 2013, reportedly clustering into MICs groups of  $< 2$  mg/l and  $\geq 2$  mg/l.<sup>12</sup> ST239-TWs isolated during that outbreak all carry the plasmid borne *qacA* gene, which encodes a major facilitator superfamily efflux-pump that expels quaternary ammonium compounds and biguanides such as chlorhexidine, and has been associated with biocide tolerance. Carriage of *qacA* currently represents the accepted explanation for the lack of clinical effect of chlorhexidine on Staphylococci.<sup>15–17</sup> However, small increases in staphylococcal MICs or MBCs have been reported elsewhere, for which a correlation with *qacA/B* carriage was found to be equivocal, or otherwise associated with a modest one dilution increase in MIC, but with no effect on the MBC.<sup>18–22</sup> Given that there is no internationally endorsed standard for assessing biocide MICs and MBCs, except for the CLSI guideline (biocide activity measurement)<sup>21</sup> and no epidemiological breakpoints for the resistance of the test organism (BSAC, EUCAST or CLSI), the significance of these increases is unclear; particularly since surface acting biocides are typically applied in much higher concentrations than their *in vitro* MIC or MBC.<sup>23–25</sup> Following the 2009 report on Antibiotic Resistance Effects of Biocides by the Scientific Committee on Emerging and Newly Identified Health Risks<sup>26</sup> Morrissey *et al.* established in 2014 the first epidemiological breakpoints characterizing *S. aureus* chlorhexidine resistance, setting the chlorhexidine MIC ECOFF at 8 mg/ml and the MBC ECOFF at  $>64$  mg/ml.<sup>27</sup> Despite working on a similar size *S. aureus* strain collection, Furi *et al.* were not able to set such breakpoints.<sup>21</sup>



One potential alternative survival mechanism to antimicrobials in bacteria is that of evading topical biocide action by invading human epithelial cells and hiding in an intracellular location. Indeed, staphylococcal adhesion, invasion and persistence has been observed in multiple human cell types (by professional and non-professional phagocytosis) and has been demonstrated as a means of evading the host innate immunity, also fostering deeper tissue and systemic infections, in addition to being postulated as a mode of surviving antibiotic action.<sup>28–33</sup>

*S. aureus* adhesion and internalization to human endothelial and epithelial cells via binding to fibrinogen and fibronectin has been widely studied,<sup>34–38</sup> and has to be included when investigating bacterial invasion into host cells. The fact that blood stream infection (BSI) isolates of ST239-TW with moderate chlorhexidine susceptibilities can persist after topical decolonization and thus outlive other clones requires detailed examination.<sup>4,8,13,38</sup> We therefore sought to investigate whether ST239-TW isolates present with a biocide evasion strategy, based on a dominant keratinocyte adhesion and internalization phenotype and if this a plausible alternative mechanism of decolonization tolerance over other MRSA clones.

## METHODS

### Bacterial strains and growth conditions

A representative collection of six ST36 (three *qacA*<sup>+</sup> and three *qacA*<sup>−</sup>), six ST22 (three *qacA*<sup>+</sup> and three *qacA*<sup>−</sup>) and six ST239-TW isolates (all *qacA*<sup>+</sup>; no *qacA*<sup>−</sup> strain initially isolated) were selected from a previously published strain set of 136 MRSA bloodstream infection isolates (BSI), from GSTT ICU patients between 2001 and 2009 (Supplementary Material Tables S1-3).<sup>12</sup> The strains were chosen based on

their previously established, comparable and highly susceptible CHG MIC result (all <2 mg/l; Supplementary Material Table S4).

BSI strain characteristics are stated in the Supplementary Material (Tables S1-3).

*S. aureus* NCTC 10788, a standard strain for chemical disinfection testing, was obtained from Public Health England and used as a quality control strain in CHG susceptibility testing.

### **In vitro chlorhexidine digluconate susceptibility testing**

MICs were determined using a modified Clinical and Laboratory Standard Institute (CLSI) micro-dilution method,<sup>40</sup> with adaptations described by Longtin *et al.* (2011).<sup>41</sup>

A 2-fold serial dilution was prepared from a 20% (w/v) chlorhexidine digluconate stock solution (CHG) (Sigma-Aldrich, Ltd. UK) and final concentrations of 64 to 0.125 mg/l were tested against  $5 \times 10^5$  CFU/ml bacteria suspensions.

### **Bacterial binding to human immobilized fibrinogen and fibronectin**

The adherence assay was performed using 10 µg/ml human fibrinogen or fibronectin (Merck Chemicals Ltd, UK). Aliquots of 100 µL stationary or exponential phase bacterial cultures were added to protein coated wells and incubated for 2 hours at 37°C. Bound bacteria were fixed with 25% formaldehyde and then stained with 0.1% crystal violet. Absorbance was measured at 570 nm (SpectraMax 190 Absorbance Microplate Reader, Molecular Devices) and readings corrected for background measurement with a bacteria-free control. *S. aureus* 8325-4 (fibronectin binding) or *S. aureus* Newman (fibrinogen binding) were included as binding controls.<sup>42</sup>

### **Cell culture adhesion and internalization assay**

HaCaT cell line maintenance: The immortalized human keratinocyte cell line (HaCaT) was maintained at 37°C (5% CO<sub>2</sub> atmospheric pressure) in T75 or T175 flasks with DMEM medium (Lonza Ltd., Belgium), supplemented with 10% foetal calf serum (FCS) (First Link Ltd., UK) and 1% penicillin-streptomycin, 50 IU/ml (Life Technologies Inc., UK).

#### Combined bacterial adhesion and invasion assay

Bacterial adhesion and invasion of human epithelial cells was assayed as previously described<sup>34,37,43</sup> with the following modifications: Briefly, HaCaT cells (4.5 x 10<sup>4</sup> cells/ml) were seeded onto circular glass coverslips (13 mm diameter, VWR 632-0150) in 24-well tissue culture plates containing DMEM/10% FCS and 1% penicillin-streptomycin and grown to 80-90% confluency. Bacterial cultures were grown at 37°C in Brain Heart Infusion (BHI) broth to stationary phase, centrifuged, washed and re-suspended in DMEM/10% FCS without antibiotics. A 1 x 10<sup>6</sup> CFU/ml bacterial aliquot was added to each well of confluent HaCaT cells, incubated for 90 minutes at 37°C (5% CO<sub>2</sub>), after which cells were carefully washed three times with PBS to remove non-adherent bacteria. The bacterial input CFU was checked for accuracy by serial dilution and plating onto BHI agar and colony counting after overnight incubation. For the combined adhesion and internalization assays, 0.5% trypsin (Worthington Biochemical Corp.) was added for 10 minutes at 37°C, to detach cells, and then neutralized with 1 ml DMEM/10% FCS. Cell suspensions were centrifuged (SIGMA 1-14 Microfuge, SciQuip Ltd.) at 14,800 rpm for 20 minutes and the mixed HaCaT/bacteria pellet resuspended in de-ionized water for 30 minutes to lyse the eukaryotic cells. Released bacteria were enumerated after overnight growth at 37°C on BHI agar to establish the proportion of both bound and internalized bacteria combined as CFU/ml.

Bacterial invasion assay: The internalization assays were performed as described for the combined adhesion and uptake assay, only that after the 90 minute co-incubation of cells and bacteria and the three PBS washes, extracellular adhered and non-adhered bacteria were killed by adding 50 µg/ml lysostaphin in DMEM/10% FCS for 1 hour at 37°C. Externally killed bacteria were washed off using PBS. Detachment of HaCaT cells from the coverslip, cell lysis and bacterial enumeration of internalized bacteria was performed as described above. The HaCat cell viability, when incubated with 50 µg/ml lysostaphin for 1 hour and also the bacterial killing efficiency with 50 µg/ml lysostaphin was confirmed using the non-toxic *AlamarBlue*<sup>®</sup> assay (Supplementary Material Figures S3 and S4).

Bacterial adhesion assay: Bacterial adhesion was calculated by subtracting CFUs/ml obtained from the internalization assay from CFUs/ml obtained from the combined adhesion and internalization assay. The final percentage of adhesion and uptake was calculated in relation to the total CFU input for each bacterial strain.

### **Chlorhexidine (CHG) killing efficiency**

The combined adhesion and internalization assay was performed as described above, to test for superficial CHG efficacy on a keratinocyte-MRSA co-culture. No differentiation between internalized and adhered bacteria was made. After washing off extracellular non-adhered bacteria, CHG was added to the Staphylococci/HaCaT cell co-culture at a final concentration of 6 mg/l and incubated at 37°C for 1 hour, followed by a final PBS wash to remove the CHG solution and non-adhered bacteria. Intracellular killed bacteria by CHG could not be eliminated at this point. Lysostaphin was not applied in this assay, as the CHG activity was investigated on adhered and internalized bacteria combined. The HaCat cell viability, when incubated with 6

mg/ml CHG, was confirmed using the non-toxic *alamarBlue*<sup>®</sup> assay (Supplementary Material, Figure S2).

Detachment of HaCaT cells from the coverslip, cell lysis and bacterial enumeration of internalized and adhered bacteria was performed as described above. The final percentage of both, adhered and internalized bacteria surviving the CHG treatment was assessed in relation to the internalization and adhesion CFU result where no CHG was added, thus for each individual bacterial strain. The results for all strains belonging to the same clone were averaged and shown as the percentage CHG survival, representing the CHG efficacy.

#### **Electron microscopy – Visualization of adhered and internalized ST239-TW**

Transmission Electron Microscopy (TEM) and Scanning Electron Microscopy (SEM) were performed on  $4.5 \times 10^4$  HaCaT cells/ml grown to 80-90% confluency on Nunc<sup>™</sup> Thermanox<sup>™</sup> coverslips (Thermo Fisher Scientific Inc.) in a 24-well tissue culture plate at 37°C in 5% CO<sub>2</sub>. Eukaryotic cells were subsequently incubated with stationary phase grown ST239-TW ( $1 \times 10^6$  CFU/ml) for 90 minutes under the same growth conditions. HaCaT cell monolayers were washed three times with PBS to remove non-adhered bacteria, not followed by lysostaphin treatment, to allow visualization of adhered as well as internalized bacteria.

For TEM, the epithelial monolayers were fixed with 2.5% (v/v) glutaraldehyde in 0.1M cacodylate buffer (pH 7.3) at 4°C for 4 hours. After rinsing thoroughly with cacodylate buffer, samples were post-fixed with 1% (w/v) osmium tetroxide in 0.1M cacodylate buffer (pH 7.3) for 1 hour at 4°C. Samples were then dehydrated through a graded ethanol series, equilibrated with propylene oxide before infiltration with TAAB epoxy resin and polymerised at 70°C for 24 hours. Ultrathin sections (50-70 nm) were

prepared using a Reichert-Jung Ultracut E ultramicrotome, mounted on 150 mesh copper grids and contrasted using uranyl acetate and lead citrate. Samples were examined on an FEI Tecnai 12 transmission microscope operated at 120 kV and images were acquired with an AMT 16000M camera.

For SEM, the HaCaT cell monolayers were fixed with 4% (v/v) paraformaldehyde. Before further processing, the samples were placed into 3% (v/v) glutaraldehyde in 0.1M cacodylate buffer (pH 7.3) and incubated for 24 hours. Finally, the samples were dehydrated for 10 minutes each in 20, 50, 70 and 90% ethanol, followed by 30 minutes incubation in 100% ethanol and a final drying step using hexamethyldisilazane. The samples were mounted onto stubs with a conducting carbon cement applied between, coated with gold and the images assessed with an FEI Quanta 3D FEG scanning electron microscope.

### Statistical methods

All experiments were performed on six ST36, six ST22 and six ST239-TW isolates, where each isolate was tested in triplicates on at least two independent occasions and the results shown as the average derived from all strains per clonal group. Statistical analysis was performed using GraphPad Prism 6.0 software. The two tailed non-parametric *t* test (Mann-Whitney ranked sum test) was applied to find differences between ST239-TW to ST22 and ST36 and the control strains, as well as *qacA*<sup>+</sup> and *qacA*<sup>-</sup> strains (MICs). Minimum statistical significance was set to  $P < 0.05$ .

## RESULTS

### Chlorhexidine (CHG) MICs

Six *qacA*<sup>+</sup> ST239-TW, three *qacA*<sup>+</sup> and three *qacA*<sup>-</sup> ST36 and ST22 MRSA BSI isolates with comparable low MICs (Supplementary Material Table S4) were randomly selected from an initial 136 isolate cohort<sup>12</sup> and multiple replicate CHG testing performed to verify their initially established MICs (Table 1). Re-testing showed only minor differences in the clones' CHG susceptibilities compared to 2013 (Supplementary Material Table S4). The highest change in MIC was found for the ST22 clones, showing an increase of 45% compared to 2013. MICs of *qacA*<sup>+</sup> and *qacA*<sup>-</sup> ST36 and ST22 clones ( $1.75 \text{ mg/l} \pm 0.05$  vs  $1.47 \text{ mg/l} \pm 0.08$ ,  $P = 0.29$ ) were similar. The fact that all ST239-TW isolates from the initial cohort were *qacA*<sup>+</sup> needs to be noted. These results confirm the 2013 established low MICs and imply that *qacA* carriage alone cannot explain the in vivo chlorhexidine survival of ST239-TW at the intensive care unit (ICU) of Guy's and Thomas' Hospital. So, we investigated cell adhesion and uptake as an additional explanation for their survival under topically applied chlorhexidine pressure in a clinical setting.

### Protein binding assay

Binding of MRSA clones to fibrinogen and fibronectin at stationary and exponential growth phases was first investigated (Figure 1). In general, protein binding was either equal or higher at stationary than at exponential bacterial growth phase. There were however clear differences between protein binding of the clonal groups in each growth phase. ST239-TW binding to both fibrinogen (OD<sub>570nm</sub> absorption: stationary 0.192; exponential 0.165) and fibronectin (stationary 0.350; exponential 0.172) was significantly higher than for ST22, ST36 and the control strains ( $P < 0.001$ ) at exponential and stationary growth phases, with the exception of ST36 at exponential growth (fibronectin 0.077,  $P = 0.195$ ; fibrinogen 0.089, 0.175,  $P = 0.211$ ).

### **Adhesion to and internalization into human keratinocytes**

Adherence and internalization of MRSA clones was assessed in vitro using an immortalized keratinocyte cell line (HaCaT) (Figure 2). Here, only the adhesion and invasion propensities between the three clones was investigated, and not their survival or persistence, to provide preliminary data for further CHG effectiveness testing on *S. aureus* bound and internalized to HaCaT cells. The co-culture incubation time was set to 90 minutes only, to minimize HaCaT cell degradation and apoptotic processes.

Electron micrographs of HaCaT cells inoculated with the representative isolate ST239-TW (TW20), confirmed bacterial adhesion and internalization (Figure 3) to HaCaT cells. TW20 bacteria were found on the keratinocyte surface (SEM) and during different stages of internalization (TEM – cross section of co-cultured bacteria with HaCaT cells), either in the process of binding, inside the epithelial cells enclosed within vacuoles, or appearing in the cell cytosol. No quantitative assessment was made.

The percentage of inoculated ST239-TW, then binding to HaCaT cells (16.39%) was significantly greater than for ST22 (9.44%;  $P = 0.0021$ ) and ST36 (4.73%;  $P < 0.0001$ ). Also, with 0.41%, a greater proportion of inoculated ST239-TW bacteria internalized into keratinocytes than ST22 (0.22%;  $P = 0.0126$ ) and ST36 (0.09%;  $P < 0.0001$ ).

### **Chlorhexidine (CHG) efficacy on co-adhered and internalized MRSA to keratinocytes**



CHG at 6 mg/l, which is more than twice the MIC of all tested MRSA clones (Table 1), resulted in 100% killing of bacteria without HaCaT cells (data not shown) and had only minimal cytotoxic effect on the HaCaT cell viability over 4 hours of incubation when tested without bacteria (Supplementary Material Figure S2).

CHG treatment, of infected (bound and internalized bacteria) monolayers showed about a three-fold greater recovery of ST239-TW (12.79% survival;  $P < 0.001$ ) compared with ST22 (3.18%) and ST36 (4.57%), but all three clinical clones were less likely to be killed by CHG than the control strains *S. aureus* Newman and *S. aureus* 8325-4 ( $< 0.7\%$ ;  $P < 0.0001$ ) (Table 2).

## DISCUSSION

The widespread use of biocides for decolonization has become an important infection control intervention to decrease transmission of nosocomial pathogens, but has also raised concerns about the development of bacterial biocide tolerance.<sup>13,16,44,45</sup> Here we show evidence that bacterial uptake into skin cells together with extracellular adherence can protect some MRSA clones against biocide action. This provides a putative mechanism whereby ST239-TW was able to resist chlorhexidine when introduced on the ICU of GSTT, in the absence of a measurable difference in MIC. Although it had previously been suggested that *qacA* and *B* carriage confers chlorhexidine tolerance,<sup>15–17</sup> our results can only partially support this. However, any effects of subtle increases of CHG MIC on ST239-TW internalized and adhered to keratinocytes were not evaluated and further, no distinction between *qacA*<sup>+</sup> and *qacA*<sup>-</sup> isolates was possible. An alternative mechanism suggested by our data is that ST239-TW has a selective advantage compared to ST22 and ST36 clones during topical chlorhexidine treatment due to its

enhanced ability to bind and invade skin cells. A further possibility, though not investigated here, is the correlation of *qacA/B* carriage with an *agr* (quorum-sensing operon) dysfunction, recently described by Cho *et al.*, suggesting a selection advantage of ST239 clones over others in an ICU with common chlorhexidine usage.<sup>46</sup>

Staphylococcal adhesion, invasion and persistence has been observed in multiple human cell types and has been postulated as a means of evading the host innate immunity and antibiotic action, leading to either recurrent or chronic infections.<sup>28–32</sup> However, the preliminary findings presented here support an additional hypothesis that by invading and adhering to skin cells, *S. aureus* (ST239-TW) is also protected against the important infection control intervention of chlorhexidine decolonization in healthcare settings. Binding to fibrinogen and fibronectin are key steps in staphylococcal adhesion and invasion, and thus are of relevance in disease pathogenesis.<sup>34–37</sup> We found that compared with ST22 and ST36, ST239-TW showed increased binding to fibrinogen and fibronectin, and increased adherence and internalization into keratinocyte monolayers. This supports the clinical phenomenon of *in vivo* chlorhexidine survival. However, we must note that common experimental investigations for *S. aureus* and eukaryotic cell interactions *in vitro* perform co-incubation for around one hour,<sup>34,37,43</sup> which does not fully represent a long-term clinical exposure to MRSA, but certainly allows for the identification of differences between MRSA clones, whilst minimizing cell apoptotic side effects.<sup>43,47</sup> The previous finding that some ST239 clones exhibit increased colonization potential to human nasal epithelial cells due to carriage of *sasX*, a mobile genetic element–encoded gene<sup>48</sup> also carried by ST239-TW<sup>49</sup> but not tested in this study, provides

supporting evidence that host cell linked CHG survival, as also shown elsewhere<sup>28–31</sup> is an important virulence mechanism of this clone.

Persistent skin colonization during antiseptic decolonization is a concern not only for patients on ICUs. It could enable colonization of catheters leading to bacteremia<sup>50</sup> and colonization of healthcare workers' hands facilitating transmission to other patients.<sup>14</sup> Chlorhexidine is used extensively in hospitals for skin cleansing prior to invasive procedures and to remove antimicrobial resistant bacteria to prevent transmission or infection.<sup>51–53</sup> However, skin traumas which are often present in ICU patients due to surgery, intubation or intravenous catheter insertion, allow the exposure of extracellular matrix proteins on the epithelial surface, thus presenting excellent initial binding conditions for MRSA isolates. Indeed, the ST239-TW MRSA strains tested in this study showed elevated survival to CHG *in vitro* when adhered and internalized to keratinocyte monolayers. Similarly Lehar *et al.* showed that a minority of MRSA can actually survive in macrophages, even under antibiotic pressure, and retain their ability to establish infections.<sup>32</sup>

Recent clinical studies have observed high rates of *qacA* carriage by Staphylococci including those isolated from healthcare workers, and in some studies that has been linked with extensive chlorhexidine use.<sup>54,55</sup> Connecting multi-drug efflux pumps such as the one encoded by *qacA* to a decreased staphylococcal susceptibility against cationic antiseptic agents (e.g. chlorhexidine) seems to be reasonable, but remains controversial.<sup>15,16,20,21,45</sup> In contrast with previous findings, showing a two- to four-fold increase in chlorhexidine MBC of five tested *qacA*<sup>+</sup> ST239-TW skin isolates,<sup>13</sup> no conclusion could be drawn from our ST239-TW BSI isolates, since all strains

specifically selected, had a moderate MIC below 2 mg/l, despite being *qacA*<sup>+</sup>. It is possible that the elevated MBC phenotype from skin isolates analyzed shortly after the outbreak at GSTT may have been lost after storage. Conversely, serial passaging of six ST239-TW isolates whilst exposed to sub-inhibitory CHG concentrations in vitro did not increase their MICs (Supplementary Material Figure S1). Consistent with other studies, we showed that biocide activity is not, or only partially affected by the presence of a *S. aureus* efflux pump.<sup>18,19,21</sup> Nevertheless, we cannot exclude that *qacA* carriage plays a role in the in vivo ST239-TW chlorhexidine tolerance phenotype.<sup>13,50</sup> It remains possible that unknown factors are required to demonstrate the chlorhexidine resistance phenotype of *qacA*<sup>+</sup> strains in the laboratory.

The findings presented here provide evidence to support the hypothesis that the clinical chlorhexidine phenotype (*in vivo* decolonization tolerance) of some MRSA clones may be due to adhesion and intracellular invasion of keratinocytes. However, further experiments will be required, with prolonged chlorhexidine exposure and antibiotic co-treatment in primary cell cultures and skin models<sup>56,57</sup> to examine the effects of keratinocyte antimicrobial peptides,<sup>58</sup> and to extend our findings by identifying the bacterial factors involved in protection against chlorhexidine and additionally investigate the consequences of intracellular survival on the host cells. Also, the relative importance of adhesion versus internalization and whether this phenomenon is associated with other clones with a similar in vivo phenotype needs to be established. Although our findings need further investigation, we feel that there is compelling evidence that the host cell invasion mechanism employed by MRSA

strains to evade innate immunity also confers tolerance to infection control interventions, which is of high clinical importance.

## **FUNDING**

This work was supported by a PhD Health School Studentship at King's College London, UK (with funding from the Faculty of Life Sciences & Medicine, the UK Engineering and Physical Sciences Research Council and the UK Medical Research Council), awarded to RD Harvey, JD Edgeworth and H Marbach. Jonathan D. Edgeworth received funding from the National Institute for Health Research (NIHR), Guy's and St Thomas' NHS Foundation Trust and Kings College London, Biomedical Research Centre and the Programme of Infection and Immunity (RJ112/N027).

## **ACKNOWLEDGEMENTS**

We thank Amita Patel from GSTT for her excellent technical advice with the MIC assay and her previous work on the blood stream infection isolates, Daniel Matthews and Roland Fleck from the Centre for Ultrastructural Imaging at King's College London, Katarzyna Niemiec and Ngoc Thuan Khanh Nguyen for their guidance during the cell culture work, Naseem Mushtaq for her thoughts on the adhesion and internalization experiment and are grateful for Barts and The London School of Medicine and Dentistry at Queen Mary, University of London for kindly providing the immortalized keratinocyte cell line (HaCaT) used for the in vitro studies.

## **POTENTIAL CONFLICTS OF INTEREST**

Jonathan A. Otter is a consultant to Gama Healthcare Ltd., and Pfizer Ltd.. All other authors have no conflicts to declare.

## REFERENCES

- 1 Ellington Matthew J, Hope Russell, Livermore David M, Kearns Angela M, Henderson Katherine, Cookson Barry D, et al. Decline of EMRSA-16 amongst methicillin-resistant *Staphylococcus aureus* causing bacteraemias in the UK between 2001 and 2007. *J Antimicrob Chemother* 2010;**65**(3):446–8. Doi: 10.1093/jac/dkp448.
- 2 Holden Matthew TG, Hsu Li-Yang, Kurt Kevin, Weinert Lucy A, Mather Alison E, Harris Simon R, et al. A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant *Staphylococcus aureus* pandemic. *Genome Res* 2013;**23**(4):653–64. Doi: 10.1101/gr.147710.112.
- 3 Johnson Alan P, Pearson Andrew, Duckworth Georgia. Surveillance and epidemiology of MRSA bacteraemia in the UK. *J Antimicrob Chemother* 2005;**56**(3):455–62. Doi: 10.1093/jac/dki266.
- 4 Edgeworth Jonathan D. Has decolonization played a central role in the decline in UK methicillin-resistant *Staphylococcus aureus* transmission? A focus on evidence from intensive care. *J Antimicrob Chemother* 2011;**66 Suppl 2**(Figure 2):ii41-7. Doi: 10.1093/jac/dkq325.
- 5 Health Department of. *The Health Act 2006: Code of practice for the prevention and control of healthcare associated infections*. Department of Health, Richmond House, 79 Whitehall, London SW1A 2NJ, UK, dhmail@dh.gsi.gov.uk; 2008.
- 6 Coia JE, Duckworth GJ, Edwards DI, Farrington M, Fry C, Humphreys H, et al. Guidelines for the control and prevention of methicillin-resistant *Staphylococcus*

- aureus (MRSA) in healthcare facilities. *J Hosp Infect* 2006;**63 Suppl 1**:S1-44. Doi: 10.1016/j.jhin.2006.01.001.
- 7 Pearson Andrew, Chronias Andrew, Murray Miranda. Voluntary and mandatory surveillance for methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-susceptible *S. aureus* (MSSA) bacteraemia in England. *J Antimicrob Chemother* 2009;**64 Suppl 1**(suppl\_1):i11-7. Doi: 10.1093/jac/dkp260.
- 8 Batra Rahul, Cooper Ben S, Whiteley Craig, Patel Amita K, Wyncoll Duncan, Edgeworth Jonathan D. Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant *Staphylococcus aureus* in an intensive care unit. *Clin Infect Dis* 2010;**50**(2):210–7. Doi: 10.1086/648717.
- 9 Climo Michael W, Yokoe Deborah S, Warren David K, Perl Trish M, Bolon Maureen, Herwaldt Loreen a, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. *N Engl J Med* 2013;**368**(6):533–42. Doi: 10.1056/NEJMoa1113849.
- 10 Cheng Vincent Chi-Chung Chung, Tai Josepha Wai-Ming Ming, Chau Pui-Hing Hing, Chen Jonathan Hon-Kwan Kwan, Yan Mei-Kum Kum, So Simon Yung-Chun Chun, et al. Minimal intervention for controlling nosocomial transmission of methicillin-resistant *Staphylococcus aureus* in resource limited setting with high endemicity. *PLoS One* 2014;**9**(6):e100493. Doi: 10.1371/journal.pone.0100493.
- 11 Harris Simon R, Feil Edward J, Holden Matthew TG, Quail Michael A, Nickerson Emma K, Chantratita Narisara, et al. Evolution of MRSA during hospital transmission and intercontinental spread. *Science* 2010;**327**(5964):469–74. Doi: 10.1126/science.1182395.

- 12 Otter Jonathan a, Patel Amita, Cliff Penelope R, Halligan Eugene P, Tosas Olga, Edgeworth Jonathan D. Selection for qacA carriage in CC22, but not CC30, methicillin-resistant *Staphylococcus aureus* bloodstream infection isolates during a successful institutional infection control programme. *J Antimicrob Chemother* 2013;**68**(5):992–9. Doi: 10.1093/jac/dks500.
- 13 Batra Rahul, Cooper Ben S, Whiteley Craig, Patel Amita K, Wyncoll Duncan, Edgeworth Jonathan D. Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant *Staphylococcus aureus* in an intensive care unit. *Clin Infect Dis* 2010;**50**(2):210–7. Doi: 10.1086/648717.
- 14 Cooper Ben S, Kypraios Theodore, Batra Rahul, Wyncoll Duncan, Tosas Olga, Edgeworth Jonathan D. Quantifying type-specific reproduction numbers for nosocomial pathogens: evidence for heightened transmission of an Asian sequence type 239 MRSA clone. *PLoS Comput Biol* 2012;**8**(4):e1002454. Doi: 10.1371/journal.pcbi.1002454.
- 15 Costa Sofia Santos, Viveiros Miguel, Amaral Leonard, Couto Isabel. Multidrug Efflux Pumps in *Staphylococcus aureus*: an Update. *Open Microbiol J* 2013;**7**:59–71. Doi: 10.2174/1874285801307010059.
- 16 Smith Karen, Gemmell Curtis G, Hunter Iain S. The association between biocide tolerance and the presence or absence of qac genes among hospital-acquired and community-acquired MRSA isolates. *J Antimicrob Chemother* 2008;**61**(1):78–84. Doi: 10.1093/jac/dkm395.
- 17 Kampf G. Acquired resistance to chlorhexidine – is it time to establish an ‘antiseptic stewardship’ initiative? *J Hosp Infect* 2016;**94**(3):213–27. Doi: 10.1016/j.jhin.2016.08.018.



- 18 Hijazi Karolin, Mukhopadhyaya Indrani, Abbott Felicity, Milne Kathleen, Al-Jabri Zaaime J, Oggioni Marco R, et al. Susceptibility to chlorhexidine amongst multidrug-resistant clinical isolates of *Staphylococcus epidermidis* from bloodstream infections. *Int J Antimicrob Agents* 2016. Doi: 10.1016/j.ijantimicag.2016.04.015.
- 19 Longtin Jean, Seah Christine, Siebert Krystal, McGeer Allison, Simor Andrew, Longtin Yves, et al. Distribution of antiseptic resistance genes *qacA*, *qacB*, and *smr* in methicillin-resistant *Staphylococcus aureus* isolated in Toronto, Canada, from 2005 to 2009. *Antimicrob Agents Chemother* 2011;**55**(6):2999–3001. Doi: 10.1128/AAC.01707-10.
- 20 Conceição Teresa, Coelho Céline, Lencastre Hermínia De, Aires-de-Sousa Marta, de Lencastre Hermínia, Aires-de-Sousa Marta. High Prevalence of Biocide Resistance Determinants in *Staphylococcus aureus* Isolates from Three African Countries. *Antimicrob Agents Chemother* 2016;**60**(1):678–81. Doi: 10.1128/AAC.02140-15.Address.
- 21 Furi Leonardo, Ciusa Maria Laura, Knight Daniel, Di Lorenzo Valeria, Tocci Nadia, Cirasola Daniela, et al. Evaluation of reduced susceptibility to quaternary ammonium compounds and bisbiguanides in clinical isolates and laboratory-generated mutants of *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2013;**57**(8):3488–97. Doi: 10.1128/AAC.00498-13.
- 22 McNeil J Chase, Kok Eric Y, Vallejo Jesus G, Campbell Judith R, Hulten Kristina G, Mason Edward O, et al. Decreased susceptibility to chlorhexidine among nosocomial *Staphylococcus aureus* at Texas Children's Hospital: Clinical and Molecular Features. *Antimicrob Agents Chemother* 2015;**60**(2):1121–8. Doi: 10.1128/AAC.02011-15.

- 23 Horner Carolyne, Mawer Damien, Wilcox Mark. Reduced susceptibility to chlorhexidine in staphylococci: is it increasing and does it matter? *J Antimicrob Chemother* 2012;**67**(11):2547–59. Doi: 10.1093/jac/dks284.
- 24 Harbarth S, Tuan Soh S, Horner C, Wilcox MHH. Is reduced susceptibility to disinfectants and antiseptics a risk in healthcare settings? A point/counterpoint review. *J Hosp Infect* 2014;**87**(4):194–202. Doi: 10.1016/j.jhin.2014.04.012.
- 25 Reichel Mirja, Heisig Peter, Kampf Günter. Pitfalls in efficacy testing--how important is the validation of neutralization of chlorhexidine digluconate? *Ann Clin Microbiol Antimicrob* 2008;**7**(1):20. Doi: 10.1186/1476-0711-7-20.
- 26 Scientific Committee on Emerging and Newly-Identified Health Risks. *Assessment of the Antibiotic Resistance Effects of Biocides*. Brussels, Belgium: European Commission; 2009. [http://ec.europa.eu/health/ph\\_risk/committees/04\\_scenihp/docs/scenihp\\_o\\_021.pdf](http://ec.europa.eu/health/ph_risk/committees/04_scenihp/docs/scenihp_o_021.pdf) [accessed 25.09.18]
- 27 Morrissey Ian, Oggioni Marco Rinaldo, Knight Daniel, Curiao Tania, Coque Teresa, Kalkanci Ayse, et al. Evaluation of Epidemiological Cut-Off Values Indicates that Biocide Resistant Subpopulations Are Uncommon in Natural Isolates of Clinically-Relevant Microorganisms. *PLoS One* 2014;**9**(1):e86669. Doi: 10.1371/journal.pone.0086669.
- 28 Garzoni Christian, Kelley William L. Staphylococcus aureus: new evidence for intracellular persistence. *Trends Microbiol* 2009;**17**(2):59–65. Doi: 10.1016/j.tim.2008.11.005.
- 29 Foster Timothy J, Geoghegan Joan a, Ganesh Vannakambadi K, Höök Magnus. Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus. *Nat Rev Microbiol* 2014;**12**(1):49–62. Doi:

- 10.1038/nrmicro3161.
- 30 Thwaites Guy E, Gant Vanya. Are bloodstream leukocytes Trojan Horses for the metastasis of *Staphylococcus aureus*? *Nat Rev Microbiol* 2011;**9**(3):215–22. Doi: 10.1038/nrmicro2508.
- 31 Fraunholz Martin, Sinha Bhanu. Intracellular *staphylococcus aureus*: Live-in and let die. *Front Cell Infect Microbiol* 2012;**2**(April):1–10. Doi: 10.3389/fcimb.2012.00043.
- 32 Lehar Sophie M, Pillow Thomas, Xu Min, Staben Leanna, Kajihara Kimberly K, Vandlen Richard, et al. Novel antibody-antibiotic conjugate eliminates intracellular *S. aureus*. *Nature* 2015;**527**(7578):323–8. Doi: 10.1038/nature16057.
- 33 Fisher Robert A, Gollan Bridget, Helaine Sophie. Persistent bacterial infections and persister cells. *Nat Rev Microbiol* 2017;**15**(8):453–64. Doi: 10.1038/nrmicro.2017.42.
- 34 Kintarak Sompid, Whawell Simon A, Speight Paul M, Packer Samantha, Nair Sean P. Internalization of *Staphylococcus aureus* by human keratinocytes. *Infect Immun* 2004;**72**(10):5668–75. Doi: 10.1128/IAI.72.10.5668-5675.2004.
- 35 Edwards Andrew M, Potts Jennifer R, Josefsson Elisabet, Massey Ruth C. *Staphylococcus aureus* host cell invasion and virulence in sepsis is facilitated by the multiple repeats within FnBPA. *PLoS Pathog* 2010;**6**(6):e1000964. Doi: 10.1371/journal.ppat.1000964.
- 36 O'Brien Louise M, Walsh Evelyn J, Massey Ruth C, Peacock Sharon J, Foster Timothy J. *Staphylococcus aureus* clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. *Cell Microbiol* 2002;**4**(11):759–70.

- 37 Edwards Andrew M, Potter Ursula, Meenan Nicola AG, Potts Jennifer R, Massey Ruth C. Staphylococcus aureus keratinocyte invasion is dependent upon multiple high-affinity fibronectin-binding repeats within FnBPA. *PLoS One* 2011;**6**(4):e18899. Doi: 10.1371/journal.pone.0018899.
- 38 Jett Bradley D, Gilmore Michael S. Internalization of Staphylococcus aureus by Human Corneal Epithelial Cells : Role of Bacterial Fibronectin-Binding Protein and Host Cell Factors Internalization of Staphylococcus aureus by Human Corneal Epithelial Cells : Role of Bacterial Fibronectin-Bin. *Infect Immun* 2002;**70**(8):4697–700. Doi: 10.1128/IAI.70.8.4697.
- 39 Brauner Asher, Fridman Ofer, Gefen Orit, Balaban Nathalie Q. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. *Nat Rev Microbiol* 2016;**14**(5):320–30. Doi: 10.1038/nrmicro.2016.34.
- 40 CLSI. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Approved Standard, 9th Edition; M07-A9*. vol. 32. Vol. 32, N. Wayne, PA, USA: Clinical and Laboratory Standards Institute (CLSI); 2012.
- 41 Longtin Jean, Seah Christine, Siebert Krystal, McGeer Allison, Simor Andrew, Longtin Yves, et al. Distribution of antiseptic resistance genes qacA, qacB, and smr in methicillin-resistant Staphylococcus aureus isolated in Toronto, Canada, from 2005 to 2009. *Antimicrob Agents Chemother* 2011;**55**(6):2999–3001. Doi: 10.1128/AAC.01707-10.
- 42 Marbach Helene, Boakes Eve, Lynham Steven, Ward Malcolm, Otter Jonathan A, Edgeworth Jonathan D. Identification of a distinctive phenotype for endocarditis-associated clonal complex 22 MRSA isolates with reduced vancomycin susceptibility. *J Med Microbiol* 2017;**66**(5):584–91. Doi: 10.1099/jmm.0.000470.

- 43 Chi Chia Yu, Lin Chiou Feng Chia Chun, Liao I Chuang, Yao Yi Chuan, Shen Fan Ching, Liu Ching Chuan, et al. Panton-valentine leukocidin facilitates the escape of staphylococcus aureus from human keratinocyte endosomes and induces apoptosis. *J Infect Dis* 2014;**209**(2):224–35. Doi: 10.1093/infdis/jit445.
- 44 Gilbert Peter, McBain Andrew J. Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance. *Clin Microbiol Rev* 2003;**16**(2):189–208. Doi: 10.1128/CMR.16.2.189.
- 45 Muñoz-Gallego Irene, Infiesta Lucia, Viedma Esther, Perez-Montarelo Dafne, Chaves Fernando. Chlorhexidine and mupirocin susceptibilities in methicillin-resistant *Staphylococcus aureus* isolates from bacteraemia and nasal colonisation. *J Glob Antimicrob Resist* 2016;**4**:65–9. Doi: 10.1016/j.jgar.2015.11.005.
- 46 Cho Oh-Hyun, Park Ki-Ho, Song Ji Young, Hong Jeong Min, Kim Taeun, Hong Sun In, et al. Prevalence and Microbiological Characteristics of qacA/B-Positive Methicillin-Resistant *Staphylococcus aureus* Isolates in a Surgical Intensive Care Unit. *Microb Drug Resist* 2018;**24**(3):283–9. Doi: 10.1089/mdr.2017.0072.
- 47 Rollin Guillaume, Tan Xin, Tros Fabiola, Dupuis Marion, Nassif Xavier, Charbit Alain, et al. Intracellular survival of *Staphylococcus aureus* in endothelial cells: A matter of growth or persistence. *Front Microbiol* 2017;**8**(JUL):1–10. Doi: 10.3389/fmicb.2017.01354.
- 48 Li Min, Du Xin, Villaruz Amer E, Diep Binh An, Wang Decheng, Song Yan, et al. MRSA epidemic linked to a quickly spreading colonization and virulence determinant. *Nat Med* 2012;**18**(5):816–9. Doi: 10.1038/nm.2692.
- 49 Aanensen David M, Feil Edward J, Holden Matthew TG, Dordel Janina, Yeats

- Corin A, Fedosejev Artemij, et al. Whole-Genome Sequencing for Routine Pathogen Surveillance in Public Health: a Population Snapshot of Invasive *Staphylococcus aureus* in Europe. *MBio* 2016;**7**(3):e00444-16. Doi: 10.1128/mBio.00444-16.
- 50 Edgeworth Jonathan D, Yadegarfar Ghasem, Pathak Smriti, Batra Rahul, Cockfield Joshua D, Wyncoll Duncan, et al. An outbreak in an intensive care unit of a strain of methicillin-resistant *Staphylococcus aureus* sequence type 239 associated with an increased rate of vascular access device-related bacteremia. *Clin Infect Dis* 2007;**44**(4):493–501. Doi: 10.1086/511034.
- 51 Mimos Olivier, Chopra Vineet, Timsit Jean-François. What's new in catheter-related infection: skin cleansing and skin antisepsis. *Intensive Care Med* 2016;**42**(11):1784–6. Doi: 10.1007/s00134-016-4244-4.
- 52 Whitman Timothy J, Schlett Carey D, Grandits Greg a, Millar Eugene V, Mende Katrin, Hospenthal Duane R, et al. Chlorhexidine gluconate reduces transmission of methicillin-resistant *Staphylococcus aureus* USA300 among marine recruits. *Infect Control Hosp Epidemiol* 2012;**33**(8):809–16. Doi: 10.1086/666631.
- 53 Vernon Michael O, Hayden Mary K, Trick William E, Hayes Robert A, Blom Donald W, Weinstein Robert A. Chlorhexidine Gluconate to Cleanse Patients in a Medical Intensive Care Unit. *Arch Intern Med* 2009;**166**(3):306–12. Doi: 10.1001/archinte.166.3.306.
- 54 Ho Cheng-Mao, Li Chi-yuan, Ho Mao-wang, Lin Chien-Yu, Liu Shu-Hui, Lu Jang-Jih. High rate of *qacA*- and *qacB*-positive methicillin-resistant *Staphylococcus aureus* isolates from chlorhexidine-impregnated catheter-related bloodstream infections. *Antimicrob Agents Chemother*

2012;**56**(11):5693–7. Doi: 10.1128/AAC.00761-12.

- 55 Zhang M, O'Donoghue MM, Ito T, Hiramatsu K, Boost M V. Prevalence of antiseptic-resistance genes in *Staphylococcus aureus* and coagulase-negative staphylococci colonising nurses and the general population in Hong Kong. *J Hosp Infect* 2011;**78**(2):113–7. Doi: 10.1016/j.jhin.2011.02.018.
- 56 Popov Lauren, Kovalski Joanna, Grandi Guido, Bagnoli Fabio, Amieva Manuel R. Three-dimensional human skin models to understand *Staphylococcus aureus* skin colonization and infection. *Front Immunol* 2014;**5**(FEB):1–6. Doi: 10.3389/fimmu.2014.00041.
- 57 Ventress Jennifer K, Partridge Lynda J, Read Robert C, Cozens Daniel, MacNeil Sheila, Monk Peter N. Peptides from tetraspanin CD9 are potent inhibitors of *Staphylococcus aureus* adherence to keratinocytes. *PLoS One* 2016;**11**(7):1–17. Doi: 10.1371/journal.pone.0160387.
- 58 Brown Aisling F, Leech John M, Rogers Thomas R, McLoughlin Rachel M. *Staphylococcus aureus* Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design. *Front Immunol* 2014;**4**(January):507. Doi: 10.3389/fimmu.2013.00507.
- 59 Holden Matthew TG, Lindsay Jodi a, Corton Craig, Quail Michael a, Cockfield Joshua D, Pathak Smriti, et al. Genome sequence of a recently emerged, highly transmissible, multi-antibiotic- and antiseptic-resistant variant of methicillin-resistant *Staphylococcus aureus*, sequence type 239 (TW). *J Bacteriol* 2010;**192**(3):888–92. Doi: 10.1128/JB.01255-09.

## Tables

**Table 1.** Chlorhexidine (CHG) MICs for selected representative EMRSA BSI isolates

Clone	Isolates (n)	MIC mean [mg/l] $\pm$ SEM	MIC range [mg/l]
ST239-TW	6	1.29 $\pm$ 0.18	1.0 - 1.5
ST22	6	2.68 $\pm$ 0.53	1.9 - 3.3
ST36	6	1.61 $\pm$ 0.18	1.4 - 1.8
<i>S. aureus</i> 8325-4	1	0.75 $\pm$ 0.25	0.1 - 1.0
<i>S. aureus</i> Newman	1	1.13 $\pm$ 0.13	1.0 - 2.0
<i>S. aureus</i> NCTC 10788	1	0.97 $\pm$ 0.18	0.3 - 1.0

Abbreviations: MIC, minimum inhibitory concentration; EMRSA, epidemic methicillin-resistant *Staphylococcus aureus*; SEM, standard error of the mean.

Note: Results are the means of  $\geq 3$  independent experiments of each individual isolate, tested in triplicate.




**Table 2.** Killing effect of chlorhexidine (CHG) on adherent and internalized MRSA clones co-cultures with HaCaT cells.


Clone	% bacterial survival	P	95% CI
ST239-TW	12.79 ± 1.08		10.34 to 14.02
ST22	3.18 ± 0.76	***	1.44 to 4.15
ST36	4.57 ± 1.68	***	1.19 to 5.20
<i>S. aureus</i> Newman	0.13 ± 0.03	***	0.07 to 0.19
<i>S. aureus</i> 8325-4	0.66 ± 0.26	***	0.06 to 1.25

Note: Results of six ST36, six ST22 and six ST239-TW isolates are for  $\geq 2$  independent experiments performed in triplicate and are presented as the mean and standard error of the mean percentage recovery for each clone; \*\*\*P < 0.001; [non-parametric two tailed Mann Whitney U test compared to ST239-TW].

## Figures




**Figure 1. Bacterial binding to immobilized human fibrinogen (A) and fibronectin (B) at stationary (filled bars) exponential (open bars) growth phases.** Bars show the results for  $\geq 3$  independent experiments performed in triplicate (*S. aureus* Newman, *S. aureus* 8325-4, six ST36, six ST22 and six ST239-TW isolates) with the standard error of the mean for each clonal group. \* $P < 0.05$ , \*\*\* $P < 0.001$ ; [Non-parametric two tailed Mann Whitney U test compared to ST239-TW].



**Figure 2. Adherence (filled bars) and internalization (open bars) of MRSA clones to HaCaT cells.**

Results are shown for  $\geq 3$  independent experiments performed in triplicate (*S. aureus* Newman, *S. aureus* 8325-4, six ST36, six ST22 and six ST239-TW isolates) with the standard error of the mean for each clonal group. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ; [Non-parametric two tailed Mann Whitney U test compared to ST239-TW].



**Figure 3.** Electron micrographs of HaCaT cells infected with MRSA ST239-TW strain (TW20)<sup>59</sup>. SEM (A, B) of adhered ST239-TW and TEM (C, D) of surrounding, and internalized ST239-TW, either presenting in vacuoles or embedded in the cell cytoskeleton. SEM shows the top view and TEM a cross section of co-incubated HaCaT cells with ST239-TW (TW20) bacteria for one hour and a three time wash with PBS.